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Background. With direct-acting antiviral agents (DAAs), mortality rates and causes of death among persons with hepatitis C 
virus (HCV) infection may change over time. However, the emergence of such trends may be delayed by the slow progression of 
chronic hepatitis C. To date, detailed analyses of cause-specific mortality among HCV-infected persons over time remain limited.
Methods. We evaluated changes in causes of death among Swiss Hepatitis C Cohort Study (SCCS) participants from 2008 to 
2016. We analyzed risk factors for all-cause and cause-specific mortality, accounting for changes in treatment, fibrosis stage, and use 
of injectable drugs over time. Mortality ascertainment was completed by linking lost-to-follow-up participants to the Swiss Federal 
Statistical Office death registry.
Results. We included 4700 SCCS participants, of whom 478 died between 2008 and 2016. The proportion of unknown causes of 
death decreased substantially after linkage, from 42% to 10%. Leading causes of death were liver failure (crude death rate 4.4/1000 
person-years), liver cancer (3.4/1000 person-years), and nonliver cancer (2.8/1000 person-years), with an increasing proportion of 
cancer-related deaths over time. Cause-specific analysis showed that persons with sustained virologic response were less at risk for 
liver-related mortality than those never treated or treated unsuccessfully.
Conclusions. Although the expected decrease in mortality is not yet observable, causes of death among HCV-infected persons 
have evolved over time. With the wider use of DAAs, liver-related mortality is expected to decline in the future. Continued moni-
toring of cause-specific mortality will remain important to assess the long-term effect of DAAs and design effective interventions.
Keywords. cohort; hepatitis C; mortality; risk factors; Switzerland.
Hepatitis C virus (HCV) infection is a leading cause of liver-
related mortality [1, 2], responsible for about 399 000 deaths 
worldwide in 2016. With the introduction of potent direct-
acting antiviral agents (DAAs), the risk of morbidity and mor-
tality for HCV-infected persons has decreased substantially 
[3]. Causes of death are likely changing over time and with 
age, as HCV-infected people may become increasingly at risk 
of dying from non-liver-related causes, including non-liver-
related malignancies or cardiovascular diseases [4]. However, 
due to the slow natural progression of chronic hepatitis C and 
the increasing number of treatments available, such trends may 
be slow to emerge. Some studies predict a rise in liver-related 
deaths to continue for another decade [5, 6]; meanwhile, the 
number of HCV-related deaths is stable or increasing in many 
settings [7].
Various studies have analyzed mortality among HCV-
infected persons. In the United States, several studies have 
shown that HCV-related deaths disproportionally affect per-
sons born between 1945 and 1965 [8, 9]. Both a comparison 
between the Chronic Hepatitis Cohort Study and the official 
death certificates in the United States [9] and a comparison be-
tween the Swiss Hepatitis C Cohort Study (SCCS) and the death 
certificates from the Swiss Federal Statistical Office (SFSO) 
[7] showed that under-reporting of HCV infection on death 
certificates is quite common. In both the United States and 
Switzerland, HCV-related mortality increased significantly be-
tween the late 1990s and the early 2000s, whereas HIV-related 
mortality decreased and hepatitis B virus (HBV)–related mor-
tality remained relatively stable [7, 8]. In New South Wales, 
Australia, HCV notifications were linked to the death registry 
[1, 2]. When comparing mortality between HCV-infected 
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persons and the general population, both liver-related and 
drug-related death rates were about 15–16 times higher in 
Australians with HCV. In HCV-mono-infected persons, liver-
related deaths increased considerably with older age, and drug-
related death rates were higher in younger age groups [1, 2]. In 
this population, liver-related mortality remained stable between 
1997 and 2006, and drug-related mortality was relatively con-
stant between 2002 and 2006 [1, 2]. More recently, a study based 
on the US Veterans Affairs Hepatitis C Clinical Case Registry 
showed that, among HCV-infected patients treated with DAAs, 
successful treatment substantially reduced mortality, both in 
the presence and absence of advanced liver disease [10, 11].
Nevertheless, few studies have analyzed detailed patterns of 
cause-specific mortality among HCV-infected persons [12, 13]. 
We therefore investigated the risk factors and time trends for 
all-cause and cause-specific mortality among HCV-infected 
persons in the SCCS. We improved mortality ascertainment by 
linking patients who were lost to follow-up to death certificates 
from the SFSO.
METHODS
The SCCS is a prospective observational cohort study, estab-
lished in 2000, that continuously enrolls patients aged ≥18 years 
in Switzerland. Only persons who are confirmed to be anti-
HCV antibody–positive are included [14]. Eight centers are 
involved, including all 5 university hospitals in Switzerland 
(Basel, Bern, Geneva, Lausanne, Zürich), 3 large nonuniversity 
hospitals (Lugano, Neuchâtel, and St. Gallen), and some affili-
ated centers. For all persons in the SCCS, various demographic, 
psychosocial, clinical, laboratory, and treatment data were col-
lected via standardized questionnaires. The questionnaires were 
completed by physicians or study nurses during enrollment and 
at annual follow-up visits. The study was approved by all local 
ethics committees, and all persons provided written informed 
consent. For deceased persons, the cause of death was coded ac-
cording to the International Statistical Classification of Diseases 
(ICD-10) [15]. Supplementary information was also provided 
to specify if the death was related to HCV infection or due to an 
accident, a suicide, or overdose/accidental poisoning.
We included all persons enrolled before December 31, 2016 
(until when data on causes of death were compiled by the SFSO). 
We excluded those who died before January 1, 2008, because the 
new 13-digit social security number (SSN), which was needed 
for the linkage, became available only in 2008. Patients were lost 
to follow-up (LTFU) if they were not seen since August 2015 
and not known to have moved abroad or to have died. Sustained 
virologic response (SVR) was defined as an undetectable HCV 
RNA ≥12 weeks after the end of antiviral treatment.
The SFSO has monitored causes of death in Switzerland since 
1876. Causes of death are coded by ICD-10 codes based on in-
itial, consecutive, and concomitant diseases listed on the SFSO 
death certificate [16]. To complete the SCCS information on 
mortality, all SCCS participants who were declared LTFU or 
dead between January 1, 2008, and December 31, 2016, were 
linked to the SFSO death registry by exact record linkage. When 
the 13-digit SSN was available, we used it as well as the date of 
birth as linkage keys. If the SSN was not available, linkage was 
based on the dates of birth and death.
We classified the main cause of death into mutually exclu-
sive categories as described in Table  1. The “other” category 
includes all causes with a frequency <30 persons. Unnatural 
causes of death include suicide, overdose/accidental poisoning, 
and accident.
For each deceased person, we retained 1 source of informa-
tion to classify the cause according to the following rules. For 
persons linked to the death registry, we preferentially selected 
ICD-10 codes from the SFSO. When this information was not 
available or when the SFSO provided less specific information 
than the SCCS, we used the ICD-10 code from the SCCS. In 
case no ICD-10 code was available from the SFSO or the SCCS, 
we used the supplementary information from the SCCS on 
causes of death mentioned earlier. All the deceased persons who 
could not be classified following this procedure were defined as 
“unspecified.” Finally, the cause of death classification was re-
viewed by an expert clinician who corrected misclassifications 
of complex cases specific to HCV infection.
Table 1. Categories of Causes of Death
Death Cause 
Group Eligibility Criteria
Liver failure 
(other than 
liver cancer)
Selected ICD-10 codes:  
 B15–B19 (viral hepatitis)  
B94.2 (sequelae of viral hepatitis)  
K70 (alcoholic liver disease)  
K71–K77 (toxic/chronic/other liver disease)  
T86.4 (liver transplant failure and rejection)  
Z94.4 (liver transplant status)  
OR  
Death identified as physically related to HCV infection ac-
cording to information obtained at or after a SCCS visit
Liver cancer Selected ICD-10 code: C22
Nonliver cancer Selected ICD-10 codes:  
C00–C21, C23–C97 (all malignant neoplasms except liver 
cancer, including leukemia)  
D00–D48 (all in situ, benign, and unknown neoplasms)
Unnatural cause Selected ICD-10 codes:  
S00–T88 except T86.4 (injury, poisoning, and certain 
other consequences of external cause)  
V01–Y98 (external causes of morbidity and mortality)  
Z92–Z99 except Z94.4 (health service–related factor)  
OR  
Death identified as due to accident, suicide, or overdose 
of narcotics according to the SCCS
Cardiovascular Selected ICD-10 codes:  
I00–I99 (diseases of the circulatory system)
Other All the deaths with selected ICD-10 code not entering 
any of the criteria described above
Unspecified No selected ICD-10 code and no complementary in-
formation from the SCCS
Abbreviations: HCV, hepatitis C virus; ICD-10, International Classification of Diseases, 10th 
revision; SCCS, Swiss Hepatitis C Cohort Study.
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For deceased persons linked to the SFSO death registry, we 
compared the main causes of death in the SCCS and the SFSO. 
We measured the interrater agreement via Kappa statistics 
[17] first by directly comparing the ICD-10 codes for the main 
cause of death and then by using the grouped causes of death 
(Table 1).
We calculated crude mortality rates overall and for different 
time periods, both for all-cause mortality and individual death 
cause groups. We also conducted survival analysis, for which 
follow-up time was calculated from enrollment into the cohort 
or starting date of the period of interest (baseline) to the cen-
soring date (which was either the date of death or the last known 
date of being alive). When the dates of death in the SCCS and 
SFSO were different, we used the date from the SFSO.
We calculated crude cumulative incidences for each cause 
of death group, accounting for competing risk (each cause of 
death being a competing risk for the other causes) using the 
R mstate package [18]. We used univariable and multivariable 
Cox proportional hazard regression, including time-dependent 
covariables [18, 19], to determine risk factors of mortality. We 
first analyzed all-cause mortality, and then cause-specific mor-
tality, for each of the causes of death (except for “other” and 
“unspecified”). Analyses were adjusted for sex, baseline age 
(as a continuous variable with restricted cubic splines [20]), 
fibrosis score (F1 to F4), history of injection drug use (IDU; 
ever, never), and treatment status (never treated, treated with 
SVR, treated without SVR). For all-cause mortality, we also ac-
counted for the treatment history (never treated, ever treated 
and received DAA, ever treated but never received DAA). Due 
to the limited number of deceased patients who received DAAs, 
we could not add this covariable in the cause-specific analysis. 
To determine the fibrosis score, we combined information from 
liver biopsies, FibroScan analyses, and any reported cirrhosis 
during follow-up. Liver stiffness assessed by FibroScan was 
converted to Metavir scores (F1: <7.5 kPa; F2: ≥7.5 to <9.5 kPa; 
F3: ≥9.5 to <12.5 kPa; F4: ≥12.5 kPa), and reported cirrhosis 
was translated into Metavir score F4. We made no assumption 
on the possible evolution of fibrosis over time and carried the 
values forward until the next measurement or until the end of 
the study. We used multiple imputation by chained equations (R 
mice package [21]) to impute missing values of time-dependent 
covariables for the multivariable analysis (see details in the 
Supplementary Data).
For sensitivity analysis, we recalculated multivariable Cox 
proportional hazard models without multiple imputation, ex-
cluding all persons with incomplete information on treatment 
type and outcome, fibrosis score, and history of IDU at any time 
over the period of interest.
RESULTS
A total of 4700 SCCS participants were followed between 
January 1, 2008, and December 31, 2016, with 471 of them 
(10%) reported to be deceased. The SSN was available for 66.0% 
(311 of 471) of persons, and for 30.4% (143 of 471) of persons 
the SSN was missing but the date of death was known. In addi-
tion, 245 of the followed persons were LTFU, and 214 (87.3%) 
had an SSN. Overall, 361 of the 471 deceased patients and 7 
of the LTFU patients were linked to the SFSO death registry. 
Figure 1 summarizes the flowchart of the SCCS-SFSO linkage. 
Among the linked persons, the reported date of death was iden-
tical for 298 persons, was different for 54 persons (for 11, the 
difference was ±1  day), and was missing for 16 persons (in-
cluding the 7 persons LTFU who were linked).
After linkage, the date of death was known for 474 of the 
478 deceased persons and remained unknown for 4 persons. 
The median individual duration of follow-up (interquartile 
range [IQR]) was 6.5 (2.2–9.0) years. During a total of 26 114 
person-years (pyrs) of follow-up, the overall mortality rate was 
18.3/1000 pyrs (95% CI, 16.7–20.0).
Table  2 shows the baseline characteristics of all the included 
SCCS persons and of deceased persons who could or could not 
be linked to the death registry. Persons were mostly male (61.7%), 
4700 patients followed up
between 2008 and 2016
245 lost to follow-up
7 dead patients linked
with SFSO, whose death
was not notified in SCCS
361 dead patients linked
with SFSO
110 dead patients not
linked with SFSO
3984 alive by end 2016
471 dead between 2008
and 2016 or with
unknown death date
238 not linked
Figure 1.  Flowchart illustrating the linkage between the Swiss Hepatitis C Cohort Study (SCCS) and the death registry of the Swiss Federal Office of Statistics (SFSO).
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Swiss nationals (73.5%), and their median age at start of follow-up 
(IQR) was 47.5 (40.6–55.1) years. The majority (54.9%) had a his-
tory of IDU, 38.8% had received antiviral treatment, and 17.6% 
were cirrhotic. Deceased persons who could or could not be linked 
to the death registry had similar characteristics.
Of the 368 deaths linked to the death registry, the main cause 
of death was available from both SCCS and SFSO for 249 per-
sons (67.7%), and for 227 of these (91.1%) ICD-10 codes were 
provided in the SCCS. When comparing causes of death using 
ICD-10 codes, the Kappa statistic was 0.14 (40 of 227 with 
identical codes). If using grouped causes of death, the Kappa 
statistics increased to 0.45 (138 of 249 with identical causes): 
The agreement was weak for both approaches. A  comparison 
of death cause groups retrieved from the SCCS and from the 
SFSO for persons with information on cause of death from both 
sources is available in the Supplementary Data.
Liver failure was the leading cause of death, with a crude death 
rate of 4.4/1000 pyrs (95% CI, 3.6–5.2), followed by liver cancer 
(3.4/1000 pyrs; 95% CI, 2.8–4.2), nonliver cancer (2.8/1000 
pyrs; 95% CI, 2.2–3.4), unnatural causes (2.5/1000 pyrs; 95% 
CI, 2.0–3.1), other causes (2.3/1000 pyrs; 95% CI, 1.8–2.9), and 
cardiovascular causes (1.3/1000 pyrs; 95% CI, 0.9–1.7). For 46 
of the 478 deceased persons (10%), the main cause of death was 
unknown.
Figure 2 shows the evolution of crude mortality rates for all-
cause, liver failure, and liver cancer mortality over time. Similar 
curves for all the cause-of-death groups listed in Table 1. Before 
2014, the leading cause of death was liver failure, followed by 
liver cancer and nonliver cancer. In contrast, after 2014, when 
DAA became more widely available in Switzerland, liver cancer 
became the leading cause of death, followed by liver failure and 
nonliver cancer.
Figure 3 shows the cumulative incidence of causes of death 
over time. The overall probability of dying from any cause in-
creased from 1.5% after 1  year of follow-up to 13.8% after 
8 years. While liver failure remained the most common cause of 
death throughout the follow-up period, liver cancer increased 
in relative proportion from year 6 onwards.
Table  3 shows the risk factors from the multivariable Cox 
models for all-cause and cause-specific mortality in the SCCS 
over the period 2008–2016. Results from the univariable Cox 
models are presented in the Supplementary Data.
For all-cause mortality, the risk of death was increased for 
men, older persons, those with a high fibrosis stage (hazard 
ratio [HR], 3.62; 95% CI, 2.92–4.49; for those with a fibrosis 
score ≥F3 compared with ≤F2), and those with a history of 
IDU (HR, 2.01; 95% CI, 1.57–2.58). Compared with per-
sons who were never treated, the risk of death was lower for 
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Figure 2.  Crude mortality rates over the years for all-cause mortality, liver 
failure, and liver cancer mortality in the Swiss Hepatitis C Cohort Study.
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Figure 3.  Cumulative incidence of different causes of death since registration 
in the Swiss Hepatitis C cohort study (causes of death are in the same order in the 
legend and on the plot).
Table 3. Estimates of the Effect of Gender, Age, Treatment, Fibrosis Stage, 
and IDU on Mortality, From Multivariable Cox Regression Models (A) for 
All-Cause Mortality and (B) for Cause-Specific Mortality
A, All-Cause Mortality
Total: 4700 Persons
All-Cause  
(478 Deaths)
Sex
Male  
Female
P < .001  
1.0 (ref)  
0.68 (0.56−0.84)
Age at baseline, y
20  
40  
60
P < .001  
0.6 (0.37−0.97)  
1.0 (ref)  
2.51 (2.04−3.1)
Treatment status
Never treated  
Treated with DAA, SVR  
Treated with DAA, failure 
Treated with IFN, SVR  
Treated with IFN, failure
P < .001  
1.0 (ref)  
0.24 (0.09−0.63) 
0.86 (0.27−2.75) 
0.34 (0.25−0.46) 
0.86 (0.69−1.06)
Fibrosis score
F0, F1, or F2  
F3 or F4
P < .001  
1.0 (ref)  
3.62 (2.92−4.49)
IDU
Never  
Ever
P < .001  
1.0 (ref)  
2.01 (1.57−2.58)
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treated persons who reached SVR after receiving interferon 
(IFN)-based treatment (HR, 0.33; 95% CI, 0.24–0.45), and 
even slightly lower for treated persons who reached SVR after 
receiving DAAs (HR, 0.23; 95% CI, 0.08–0.63). In contrast, 
treated persons who did not achieve SVR had a risk of death 
that was comparable to those who were never treated, irrespec-
tive of type of treatment.
Older persons and those with fibrosis score ≥F3 were at 
higher risk of dying from liver failure than younger persons 
and those with a fibrosis score ≤F2. Baseline treatment status 
was associated with mortality due to liver failure, with a pro-
nounced protective effect for treated persons with SVR (HR, 
0.18; 95% CI, 0.08–0.37) but no reduction in risk for persons 
treated without SVR (HR, 0.78; 95% CI, 0.51–1.18).
For liver cancer, the risk of death was higher for older per-
sons and those with a high fibrosis stage. Having a history of 
IDU had little impact on liver cancer mortality. Compared with 
never-treated persons, the risk of dying decreased for treated 
persons with SVR (HR, 0.33; 95% CI, 0.16–0.71), but not for 
treated persons without SVR (HR, 1.34; 95% CI, 0.81–2.22).
The risk of dying from nonliver cancer was higher for older 
persons than for younger persons. Although there was no sig-
nificant association between nonliver cancer mortality and 
treatment status, nor with baseline fibrosis score, persons with a 
history of IDU were more at risk than persons without a history 
of IDU (HR, 3.22; 95% CI, 1.64–6.33).
Having ever used injectable drugs was associated with an in-
creased risk of dying from unnatural causes (HR, 3.65; 95% CI, 
1.67–7.97). In addition, persons aged 20 years were more at risk 
than persons aged 40 years or older (HR, 2.9; 95% CI, 1.21–6.9), as 
well as persons with a fibrosis score ≥F3 compared with those with 
a fibrosis score ≤F2 (HR, 1.91; 95% CI, 1.07–3.4). There was no as-
sociation between unnatural causes of death and treatment status.
Results from the sensitivity analysis were similar to the main 
analysis for all-cause mortality, but there were some notable dif-
ferences for cause-specific mortality (Supplementary Data).
DISCUSSION
Based on SCCS data, we investigated time trends and risk fac-
tors of all-cause and cause-specific mortality among HCV-
infected persons in Switzerland. Linkage of LTFU persons to 
the death registry did not significantly increase the number of 
deaths. However, the proportion of unknown causes of death 
decreased substantially after linkage, from 42% to 10%.
Leading causes of death changed over time, with a substan-
tial increase in the proportion of liver cancer–related deaths. 
Similar to other studies [7], we found that mortality remained 
stable among HCV-infected persons in Switzerland over the 
past few years.
The risk of death was lower for women (similar to other 
studies [12]), younger persons, persons with a lower fibrosis 
B, Cause-Specific Mortality
Total: 4700 Persons
Liver Failure
 
(114 Deaths, 23.8%)
Liver Cancer
 
(89 Deaths, 18.6%)
Nonliver Cancer
 
(72 Deaths, 15.1%)
Cardiovascular
 
(33 Deaths, 6.9%)
Unnatural Cause
 
(65 Deaths, 
13.6%)
Sex
Male
Female
P = .17
1.0 (ref) 
0.75 (0.49−1.14)
P = .097
1.0 (ref) 
0.67 (0.42−1.08)
P = .073
1.0 (ref) 
0.61 (0.36−1.05)
P = .043
1.0 (ref) 
0.44 (0.2−0.97)
P = .18
1.0 (ref) 
0.68 (0.39−1.19)
Age at baseline, y
20 
40 
60
P = .019 
0.27 (0.08−0.93) 
1.0 (ref) 
2.06 (1.25−3.42)
P < .001 
0.09 (0.01−0.63) 
1.0 (ref) 
6.23 (2.72−14.24)
P < .001 
0.05 (0.01−0.28) 
1.0 (ref) 
8.34 (3.96−17.58)
P < .001 
0.64 (0.07−5.47) 
1.0 (ref) 
5.4 (2.13−13.72)
P = .045 
2.9 (1.21−6.9) 
1.0 (ref) 
1.06 (0.61−1.86)
Treatment status
Never treated 
Treated with SVR 
Treated with failure
P < .001 
1.0 (ref) 
0.18 (0.08−0.37) 
0.78 (0.51−1.18)
P < .001 
1.0 (ref) 
0.33 (0.16−0.71) 
1.34 (0.81−2.22)
P = .27 
1.0 (ref) 
0.59 (0.31−1.11) 
0.84 (0.47−1.49)
P = .18 
1.0 (ref) 
0.42 (0.15−1.12) 
0.61 (0.26−1.41)
P = .17 
1.0 (ref) 
0.5 (0.24−1.03) 
0.89 (0.48−1.67)
Fibrosis score
F0, F1, or F2 
F3 or F4
P < .001 
1.0 (ref) 
13.8 (7.69−24.75)
P < .001 
1.0 (ref) 
14.09 (6.59−30.13)
P = .12 
1.0 (ref) 
1.52 (0.9−2.58)
P = .0095 
1.0 (ref) 
2.81 (1.29−6.14)
P = .028 
1.0 (ref) 
1.91 (1.07−3.4)
IDU
Never 
Ever
P = .26 
1.0 (ref) 
1.31 (0.82−2.11)
P = .19 
1.0 (ref) 
1.46 (0.83−2.56)
P < .001 
1.0 (ref) 
3.22 (1.64−6.33)
P = .17 
1.0 (ref) 
2.12 (0.73−6.18)
P = .0011 
1.0 (ref) 
3.65 (1.67−7.97)
Abbreviations: DAA, direct-acting antiviral agent; IDU, injection drug use; IFN, interferon; SVR, sustained virologic response.
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score, persons without a history of IDU, and treated persons 
who reached SVR, with a first indication of a more positive ef-
fect with DAAs compared with IFN-based treatments. However, 
in contrast to some other studies, we found little evidence that 
being treated with failure had a protective effect compared 
with remaining untreated [22, 23]. For both liver failure and 
liver cancer, the risk of dying was significantly associated with 
treatment, with a lower risk for treated persons with SVR than 
for treated persons without SVR or untreated persons. Having 
a history of IDU was an important risk factor for death from 
nonliver cancer and unnatural causes, explained by the inclu-
sion of overdose/accidental poisoning in this category.
Two factors probably explain the change in leading causes of 
death over time: Increasing age may cause more people to die 
of liver disease and more people with cirrhosis to develop liver 
cancer; and ascertainment of cause of death may have improved 
over time. Indeed, the proportion of unspecified causes of death 
decreased from 13% in 2008–2013 to 4% in 2014–2016, reflecting 
the better linkage in the later years (92% of deceased persons in 
2014–2016 were linked, compared with 67% in 2008–2013). 
Furthermore, the declining proportion of liver failure while 
increasing liver cancer might be due to more extensive ascertain-
ment of small foci of hepato-cellular carcinoma (HCC) over time.
The expected decrease in mortality due to DAA is not 
occurring, or more probably not yet observable. Indeed, some 
studies have reported a decline in mortality after the introduc-
tion of DAA, but only from 2016 onwards [13]. As data for 
wider use of DAA were only available for 3 years (2014–2016), 
a period when prescription of DAA in Switzerland was limited 
based on fibrosis stage [24–26], we were not able to evaluate 
the difference between successful IFN treatment and successful 
DAA treatment regarding liver-related mortality.
Persons who inject drugs (PWID) are a key subgroup of 
HCV-infected persons in Switzerland and other high-income 
countries, where most HCV infections occur via IDU [27, 28].
Despite the implementation of the 4-pillar strategy [29–
31], a national drug policy in Switzerland since 1994, addi-
tional obstacles exist for HCV treatment among PWID both 
for treatment providers and patients [32]. Consequently, 
some HCV-infected PWID enter care relatively late, at an 
advanced fibrosis stage. The proportion of infected PWID 
who receive anti-HCV treatments (DAA or IFN-based) has 
increased only slightly, from 51% in 2008–2013 to 58% in 
2014–2016. The waiting time to initiate DAA treatment is 
likely shorter than for IFN-based treatment, and even PWID 
who enter care late are more likely to reach favorable out-
comes with DAAs. However, persons with a history of IDU 
now have a higher risk of dying from nonliver cancer, po-
tentially related to their addiction and additional risk factors 
common among PWID, such as smoking or excessive alcohol 
consumption [33].
Differences between causes of death reported in the SFSO 
death registry and the SCCS can be partly explained by dif-
ferent coding practices. The main focus of the SCCS was likely 
to identify all HCV-related deaths, and there was less emphasis 
on recording the exact cause of death. For 21% of SCCS entries, 
cause of death was “liver failure” in 1 data set and “liver cancer” 
in the other, 2 causes that are relatively similar. Overall, clear 
discrepancies in the causes of death recorded in the SCCS and 
the SFSO exist in only 21% of cases (Supplementary Data).
To our knowledge, this is one of the first studies investigating 
detailed risk factors and time trends of cause-specific mor-
tality among HCV-infected persons. Via linkage with the death 
registry, we significantly improved information on causes of 
death. By accounting for competing risks, including age as a 
continuous covariate (and not categorizing it arbitrarily), and 
adjusting models for time-dependent covariables, we were able 
to improve the accuracy of our analysis.
A limitation of this study was the unavailability of complete 
data relating to fibrosis stage evolution. Hence, we made no as-
sumption on fibrosis evolution over time and used multiple im-
putation to handle missing values, which may compromise the 
robustness of our analysis. We did a sensitivity analysis using 
complete cases only. In this analysis, the number of persons for 
the cause-specific analysis was relatively limited, and results 
may therefore be less reliable.
In conclusion, although mortality did not (yet) decrease 
with DAA, we found that causes of death changed over time. 
With the wider use of DAA, irrespective of fibrosis stage, 
liver-related mortality will likely continue to decline in the 
future. Continuous monitoring of mortality and causes of 
death will therefore remain important to the evaluation of 
the long-term effect of DAA and to developing effective 
interventions.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 
of the authors, so questions or comments should be addressed to the 
corresponding author.
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